CAMP4 Therapeutics Corp Dossier
Qualitative Analysis
Business overview
Camp4 Therapeutics Corp (Nasdaq: CAMP) is a clinical-stage biopharmaceutical company pioneering the discovery and development of regulatory RNA-targeting (regRNA) therapeutics. Leveraging its proprietary RNA Actuator Platform (RAP Platformu0001), the company maps regRNAs to design antisense oligonucleotide (ASO) drug candidates that upregulate gene expression and restore healthy protein levels. This approach is designed to treat a broad range of genetic diseases, particularly haploinsufficient and recessive partial loss-of-function disorders. Camp4's lead pipeline programs include CMP-CPS-001, which is in clinical development for the treatment of urea cycle disorders (UCDs), and CMP-002, targeting SYNGAP1-related disorders.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Advancing lead candidate CMP-002, an intrathecally delivered antisense oligonucleotide (ASO) designed to increase SYNGAP1 gene transcription, through GLP toxicology studies and into a global Phase 1/2 clinical trial.
Expected impact: Establish clinical proof-of-concept for the RAP Platform in neurodevelopmental disorders.
Seeking strategic partnership opportunities to support the further clinical development of CMP-001 (formerly CMP-CPS-001) for urea cycle disorders, following the pause of internal investment in 2025.
Expected impact: Maximize the value of the metabolic pipeline while conserving internal capital for CNS programs.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Collaborating to identify and develop novel antisense oligonucleotide (ASO) drug candidates for multiple gene targets relevant to neurodegenerative and kidney disease indications using CAMP4's RAP Platform.
Terms: CAMP4 received a $17.5 million upfront cash payment and is eligible to receive up to $440 million in future development and commercial milestones, plus tiered royalties on future net sales.
Collaborating on assets that engage regulatory RNA (regRNA) sequences for two genetic targets.
Terms: CAMP4 received $1 million upfront and is eligible for up to $185 million per program in milestone payments.